nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PTGS1—Alzheimer's disease	0.198	0.595	CbGaD
Bortezomib—CYP2D6—Alzheimer's disease	0.134	0.405	CbGaD
Bortezomib—CYP2D6—Rivastigmine—Alzheimer's disease	0.0506	0.179	CbGbCtD
Bortezomib—CYP2C19—Memantine—Alzheimer's disease	0.0462	0.164	CbGbCtD
Bortezomib—CYP2C9—Donepezil—Alzheimer's disease	0.0443	0.157	CbGbCtD
Bortezomib—CYP2D6—Donepezil—Alzheimer's disease	0.0405	0.143	CbGbCtD
Bortezomib—CYP3A4—Rivastigmine—Alzheimer's disease	0.0322	0.114	CbGbCtD
Bortezomib—CYP2D6—Galantamine—Alzheimer's disease	0.0261	0.0924	CbGbCtD
Bortezomib—CYP3A4—Donepezil—Alzheimer's disease	0.0257	0.0912	CbGbCtD
Bortezomib—CYP3A4—Galantamine—Alzheimer's disease	0.0166	0.0588	CbGbCtD
Bortezomib—PSMA1—embryo—Alzheimer's disease	0.00345	0.064	CbGeAlD
Bortezomib—PSMD2—embryo—Alzheimer's disease	0.00257	0.0476	CbGeAlD
Bortezomib—PSMD1—telencephalon—Alzheimer's disease	0.00236	0.0437	CbGeAlD
Bortezomib—PSMD2—forebrain—Alzheimer's disease	0.00227	0.0421	CbGeAlD
Bortezomib—PSMD2—telencephalon—Alzheimer's disease	0.00209	0.0387	CbGeAlD
Bortezomib—PSMB1—embryo—Alzheimer's disease	0.00197	0.0365	CbGeAlD
Bortezomib—PSMB2—embryo—Alzheimer's disease	0.00192	0.0356	CbGeAlD
Bortezomib—PSMB5—telencephalon—Alzheimer's disease	0.00183	0.034	CbGeAlD
Bortezomib—PSMB2—forebrain—Alzheimer's disease	0.0017	0.0315	CbGeAlD
Bortezomib—PSMA1—nervous system—Alzheimer's disease	0.00166	0.0307	CbGeAlD
Bortezomib—PSMB1—telencephalon—Alzheimer's disease	0.0016	0.0297	CbGeAlD
Bortezomib—PSMA1—central nervous system—Alzheimer's disease	0.0016	0.0296	CbGeAlD
Bortezomib—PSMB2—telencephalon—Alzheimer's disease	0.00156	0.029	CbGeAlD
Bortezomib—PSMA1—cerebellum—Alzheimer's disease	0.00156	0.0289	CbGeAlD
Bortezomib—PSMD1—cerebellum—Alzheimer's disease	0.00131	0.0243	CbGeAlD
Bortezomib—PSMA1—brain—Alzheimer's disease	0.00127	0.0235	CbGeAlD
Bortezomib—PSMD2—nervous system—Alzheimer's disease	0.00123	0.0228	CbGeAlD
Bortezomib—Lacosamide—CA4—Alzheimer's disease	0.00121	0.517	CrCbGaD
Bortezomib—PSMD2—central nervous system—Alzheimer's disease	0.00119	0.022	CbGeAlD
Bortezomib—PSMD2—cerebellum—Alzheimer's disease	0.00116	0.0215	CbGeAlD
Bortezomib—PSMD1—brain—Alzheimer's disease	0.00106	0.0197	CbGeAlD
Bortezomib—PSMB5—cerebellum—Alzheimer's disease	0.00102	0.0189	CbGeAlD
Bortezomib—PSMB1—nervous system—Alzheimer's disease	0.000946	0.0175	CbGeAlD
Bortezomib—PSMD2—brain—Alzheimer's disease	0.000942	0.0175	CbGeAlD
Bortezomib—PSMB8—brain—Alzheimer's disease	0.000936	0.0174	CbGeAlD
Bortezomib—PSMB2—nervous system—Alzheimer's disease	0.000923	0.0171	CbGeAlD
Bortezomib—PSMB1—central nervous system—Alzheimer's disease	0.000911	0.0169	CbGeAlD
Bortezomib—PSMB1—cerebellum—Alzheimer's disease	0.00089	0.0165	CbGeAlD
Bortezomib—PSMB2—central nervous system—Alzheimer's disease	0.000889	0.0165	CbGeAlD
Bortezomib—PSMB2—cerebellum—Alzheimer's disease	0.000868	0.0161	CbGeAlD
Bortezomib—PTGS1—blood vessel—Alzheimer's disease	0.000833	0.0154	CbGeAlD
Bortezomib—PSMB5—brain—Alzheimer's disease	0.000827	0.0153	CbGeAlD
Bortezomib—SLC31A1—nervous system—Alzheimer's disease	0.000799	0.0148	CbGeAlD
Bortezomib—SLC31A1—central nervous system—Alzheimer's disease	0.000769	0.0143	CbGeAlD
Bortezomib—SLC31A1—cerebellum—Alzheimer's disease	0.000752	0.0139	CbGeAlD
Bortezomib—PSMB1—brain—Alzheimer's disease	0.000723	0.0134	CbGeAlD
Bortezomib—PSMB2—brain—Alzheimer's disease	0.000705	0.0131	CbGeAlD
Bortezomib—SLC31A1—brain—Alzheimer's disease	0.000611	0.0113	CbGeAlD
Bortezomib—Nateglinide—PPARG—Alzheimer's disease	0.000504	0.215	CrCbGaD
Bortezomib—PTGS1—forebrain—Alzheimer's disease	0.000439	0.00814	CbGeAlD
Bortezomib—PTGS1—telencephalon—Alzheimer's disease	0.000404	0.00749	CbGeAlD
Bortezomib—Nateglinide—PTGS1—Alzheimer's disease	0.000372	0.159	CrCbGaD
Bortezomib—CYP2D6—forebrain—Alzheimer's disease	0.000361	0.00669	CbGeAlD
Bortezomib—CYP2D6—telencephalon—Alzheimer's disease	0.000332	0.00615	CbGeAlD
Bortezomib—CYP1A1—nervous system—Alzheimer's disease	0.000271	0.00503	CbGeAlD
Bortezomib—CYP1A1—central nervous system—Alzheimer's disease	0.000261	0.00484	CbGeAlD
Bortezomib—Nateglinide—CYP2D6—Alzheimer's disease	0.000253	0.108	CrCbGaD
Bortezomib—PTGS1—nervous system—Alzheimer's disease	0.000238	0.00442	CbGeAlD
Bortezomib—PTGS1—central nervous system—Alzheimer's disease	0.00023	0.00425	CbGeAlD
Bortezomib—CYP2C8—brain—Alzheimer's disease	0.000225	0.00417	CbGeAlD
Bortezomib—CYP1A1—brain—Alzheimer's disease	0.000207	0.00384	CbGeAlD
Bortezomib—CYP3A4—nervous system—Alzheimer's disease	0.000199	0.00369	CbGeAlD
Bortezomib—CYP2D6—nervous system—Alzheimer's disease	0.000196	0.00363	CbGeAlD
Bortezomib—CYP3A4—central nervous system—Alzheimer's disease	0.000192	0.00355	CbGeAlD
Bortezomib—CYP2D6—central nervous system—Alzheimer's disease	0.000189	0.0035	CbGeAlD
Bortezomib—CYP2D6—cerebellum—Alzheimer's disease	0.000184	0.00342	CbGeAlD
Bortezomib—PTGS1—brain—Alzheimer's disease	0.000182	0.00338	CbGeAlD
Bortezomib—CYP2D6—brain—Alzheimer's disease	0.00015	0.00278	CbGeAlD
Bortezomib—Haemorrhage—Memantine—Alzheimer's disease	0.000138	0.000652	CcSEcCtD
Bortezomib—Hepatitis—Memantine—Alzheimer's disease	0.000138	0.000652	CcSEcCtD
Bortezomib—Bradycardia—Rivastigmine—Alzheimer's disease	0.000137	0.000649	CcSEcCtD
Bortezomib—Hallucination—Memantine—Alzheimer's disease	0.000137	0.000649	CcSEcCtD
Bortezomib—Hypoaesthesia—Memantine—Alzheimer's disease	0.000137	0.000649	CcSEcCtD
Bortezomib—Shock—Galantamine—Alzheimer's disease	0.000137	0.000648	CcSEcCtD
Bortezomib—Nervous system disorder—Galantamine—Alzheimer's disease	0.000136	0.000646	CcSEcCtD
Bortezomib—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000136	0.000645	CcSEcCtD
Bortezomib—Chills—Donepezil—Alzheimer's disease	0.000136	0.000644	CcSEcCtD
Bortezomib—Urinary tract disorder—Memantine—Alzheimer's disease	0.000136	0.000644	CcSEcCtD
Bortezomib—Tachycardia—Galantamine—Alzheimer's disease	0.000136	0.000643	CcSEcCtD
Bortezomib—Oedema peripheral—Memantine—Alzheimer's disease	0.000135	0.000642	CcSEcCtD
Bortezomib—Arrhythmia—Donepezil—Alzheimer's disease	0.000135	0.000642	CcSEcCtD
Bortezomib—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000135	0.000641	CcSEcCtD
Bortezomib—Connective tissue disorder—Memantine—Alzheimer's disease	0.000135	0.000641	CcSEcCtD
Bortezomib—Skin disorder—Galantamine—Alzheimer's disease	0.000135	0.000639	CcSEcCtD
Bortezomib—Urethral disorder—Memantine—Alzheimer's disease	0.000135	0.000639	CcSEcCtD
Bortezomib—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000135	0.000638	CcSEcCtD
Bortezomib—Hepatitis—Rivastigmine—Alzheimer's disease	0.000135	0.000638	CcSEcCtD
Bortezomib—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000134	0.000636	CcSEcCtD
Bortezomib—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000134	0.000635	CcSEcCtD
Bortezomib—Hallucination—Rivastigmine—Alzheimer's disease	0.000134	0.000635	CcSEcCtD
Bortezomib—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000133	0.00063	CcSEcCtD
Bortezomib—Mental disorder—Donepezil—Alzheimer's disease	0.000133	0.000629	CcSEcCtD
Bortezomib—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.000133	0.000628	CcSEcCtD
Bortezomib—Visual impairment—Memantine—Alzheimer's disease	0.000133	0.000628	CcSEcCtD
Bortezomib—Anorexia—Galantamine—Alzheimer's disease	0.000132	0.000628	CcSEcCtD
Bortezomib—Connective tissue disorder—Rivastigmine—Alzheimer's disease	0.000132	0.000627	CcSEcCtD
Bortezomib—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000132	0.000625	CcSEcCtD
Bortezomib—Erythema—Donepezil—Alzheimer's disease	0.000132	0.000625	CcSEcCtD
Bortezomib—Malnutrition—Donepezil—Alzheimer's disease	0.000132	0.000625	CcSEcCtD
Bortezomib—Erythema multiforme—Memantine—Alzheimer's disease	0.00013	0.000617	CcSEcCtD
Bortezomib—Flatulence—Donepezil—Alzheimer's disease	0.00013	0.000616	CcSEcCtD
Bortezomib—Hypotension—Galantamine—Alzheimer's disease	0.00013	0.000615	CcSEcCtD
Bortezomib—Visual impairment—Rivastigmine—Alzheimer's disease	0.00013	0.000615	CcSEcCtD
Bortezomib—Dysgeusia—Donepezil—Alzheimer's disease	0.000129	0.000612	CcSEcCtD
Bortezomib—Eye disorder—Memantine—Alzheimer's disease	0.000129	0.000609	CcSEcCtD
Bortezomib—Tinnitus—Memantine—Alzheimer's disease	0.000128	0.000608	CcSEcCtD
Bortezomib—Flushing—Memantine—Alzheimer's disease	0.000128	0.000605	CcSEcCtD
Bortezomib—Cardiac disorder—Memantine—Alzheimer's disease	0.000128	0.000605	CcSEcCtD
Bortezomib—Back pain—Donepezil—Alzheimer's disease	0.000128	0.000605	CcSEcCtD
Bortezomib—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000127	0.000603	CcSEcCtD
Bortezomib—Muscle spasms—Donepezil—Alzheimer's disease	0.000127	0.000601	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000127	0.0006	CcSEcCtD
Bortezomib—Eye disorder—Rivastigmine—Alzheimer's disease	0.000126	0.000596	CcSEcCtD
Bortezomib—Insomnia—Galantamine—Alzheimer's disease	0.000126	0.000595	CcSEcCtD
Bortezomib—Tinnitus—Rivastigmine—Alzheimer's disease	0.000125	0.000595	CcSEcCtD
Bortezomib—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000125	0.000592	CcSEcCtD
Bortezomib—Flushing—Rivastigmine—Alzheimer's disease	0.000125	0.000592	CcSEcCtD
Bortezomib—Angiopathy—Memantine—Alzheimer's disease	0.000125	0.000592	CcSEcCtD
Bortezomib—Paraesthesia—Galantamine—Alzheimer's disease	0.000125	0.000591	CcSEcCtD
Bortezomib—Vision blurred—Donepezil—Alzheimer's disease	0.000124	0.000589	CcSEcCtD
Bortezomib—Immune system disorder—Memantine—Alzheimer's disease	0.000124	0.000589	CcSEcCtD
Bortezomib—Mediastinal disorder—Memantine—Alzheimer's disease	0.000124	0.000588	CcSEcCtD
Bortezomib—Tremor—Donepezil—Alzheimer's disease	0.000124	0.000586	CcSEcCtD
Bortezomib—Chills—Memantine—Alzheimer's disease	0.000123	0.000585	CcSEcCtD
Bortezomib—Arrhythmia—Memantine—Alzheimer's disease	0.000123	0.000583	CcSEcCtD
Bortezomib—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000122	0.00058	CcSEcCtD
Bortezomib—Dyspepsia—Galantamine—Alzheimer's disease	0.000122	0.00058	CcSEcCtD
Bortezomib—Angiopathy—Rivastigmine—Alzheimer's disease	0.000122	0.000579	CcSEcCtD
Bortezomib—Anaemia—Donepezil—Alzheimer's disease	0.000122	0.000578	CcSEcCtD
Bortezomib—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000121	0.000575	CcSEcCtD
Bortezomib—Agitation—Donepezil—Alzheimer's disease	0.000121	0.000575	CcSEcCtD
Bortezomib—Chills—Rivastigmine—Alzheimer's disease	0.000121	0.000572	CcSEcCtD
Bortezomib—Decreased appetite—Galantamine—Alzheimer's disease	0.000121	0.000572	CcSEcCtD
Bortezomib—Mental disorder—Memantine—Alzheimer's disease	0.00012	0.000571	CcSEcCtD
Bortezomib—Arrhythmia—Rivastigmine—Alzheimer's disease	0.00012	0.00057	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.00012	0.000568	CcSEcCtD
Bortezomib—Malnutrition—Memantine—Alzheimer's disease	0.00012	0.000568	CcSEcCtD
Bortezomib—Fatigue—Galantamine—Alzheimer's disease	0.00012	0.000568	CcSEcCtD
Bortezomib—Malaise—Donepezil—Alzheimer's disease	0.000119	0.000564	CcSEcCtD
Bortezomib—Constipation—Galantamine—Alzheimer's disease	0.000119	0.000563	CcSEcCtD
Bortezomib—Vertigo—Donepezil—Alzheimer's disease	0.000118	0.000562	CcSEcCtD
Bortezomib—Syncope—Donepezil—Alzheimer's disease	0.000118	0.000561	CcSEcCtD
Bortezomib—Flatulence—Memantine—Alzheimer's disease	0.000118	0.000559	CcSEcCtD
Bortezomib—Mental disorder—Rivastigmine—Alzheimer's disease	0.000118	0.000559	CcSEcCtD
Bortezomib—Dysgeusia—Memantine—Alzheimer's disease	0.000117	0.000556	CcSEcCtD
Bortezomib—Erythema—Rivastigmine—Alzheimer's disease	0.000117	0.000555	CcSEcCtD
Bortezomib—Malnutrition—Rivastigmine—Alzheimer's disease	0.000117	0.000555	CcSEcCtD
Bortezomib—Loss of consciousness—Donepezil—Alzheimer's disease	0.000116	0.000549	CcSEcCtD
Bortezomib—Back pain—Memantine—Alzheimer's disease	0.000116	0.000549	CcSEcCtD
Bortezomib—Flatulence—Rivastigmine—Alzheimer's disease	0.000115	0.000547	CcSEcCtD
Bortezomib—Cough—Donepezil—Alzheimer's disease	0.000115	0.000546	CcSEcCtD
Bortezomib—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000115	0.000544	CcSEcCtD
Bortezomib—Feeling abnormal—Galantamine—Alzheimer's disease	0.000114	0.000543	CcSEcCtD
Bortezomib—Convulsion—Donepezil—Alzheimer's disease	0.000114	0.000542	CcSEcCtD
Bortezomib—Hypertension—Donepezil—Alzheimer's disease	0.000114	0.00054	CcSEcCtD
Bortezomib—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000114	0.000538	CcSEcCtD
Bortezomib—Back pain—Rivastigmine—Alzheimer's disease	0.000113	0.000537	CcSEcCtD
Bortezomib—Vision blurred—Memantine—Alzheimer's disease	0.000113	0.000535	CcSEcCtD
Bortezomib—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000113	0.000534	CcSEcCtD
Bortezomib—Arthralgia—Donepezil—Alzheimer's disease	0.000112	0.000532	CcSEcCtD
Bortezomib—Chest pain—Donepezil—Alzheimer's disease	0.000112	0.000532	CcSEcCtD
Bortezomib—Myalgia—Donepezil—Alzheimer's disease	0.000112	0.000532	CcSEcCtD
Bortezomib—Tremor—Memantine—Alzheimer's disease	0.000112	0.000532	CcSEcCtD
Bortezomib—Anxiety—Donepezil—Alzheimer's disease	0.000112	0.00053	CcSEcCtD
Bortezomib—Ill-defined disorder—Memantine—Alzheimer's disease	0.000111	0.000527	CcSEcCtD
Bortezomib—Discomfort—Donepezil—Alzheimer's disease	0.000111	0.000526	CcSEcCtD
Bortezomib—Anaemia—Memantine—Alzheimer's disease	0.000111	0.000525	CcSEcCtD
Bortezomib—Vision blurred—Rivastigmine—Alzheimer's disease	0.00011	0.000523	CcSEcCtD
Bortezomib—Agitation—Memantine—Alzheimer's disease	0.00011	0.000522	CcSEcCtD
Bortezomib—Body temperature increased—Galantamine—Alzheimer's disease	0.00011	0.00052	CcSEcCtD
Bortezomib—Abdominal pain—Galantamine—Alzheimer's disease	0.00011	0.00052	CcSEcCtD
Bortezomib—Tremor—Rivastigmine—Alzheimer's disease	0.00011	0.00052	CcSEcCtD
Bortezomib—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000109	0.000515	CcSEcCtD
Bortezomib—Confusional state—Donepezil—Alzheimer's disease	0.000109	0.000514	CcSEcCtD
Bortezomib—Anaemia—Rivastigmine—Alzheimer's disease	0.000108	0.000513	CcSEcCtD
Bortezomib—Malaise—Memantine—Alzheimer's disease	0.000108	0.000512	CcSEcCtD
Bortezomib—Agitation—Rivastigmine—Alzheimer's disease	0.000108	0.00051	CcSEcCtD
Bortezomib—Oedema—Donepezil—Alzheimer's disease	0.000108	0.00051	CcSEcCtD
Bortezomib—Vertigo—Memantine—Alzheimer's disease	0.000108	0.00051	CcSEcCtD
Bortezomib—Syncope—Memantine—Alzheimer's disease	0.000107	0.000509	CcSEcCtD
Bortezomib—Leukopenia—Memantine—Alzheimer's disease	0.000107	0.000508	CcSEcCtD
Bortezomib—Infection—Donepezil—Alzheimer's disease	0.000107	0.000507	CcSEcCtD
Bortezomib—Shock—Donepezil—Alzheimer's disease	0.000106	0.000502	CcSEcCtD
Bortezomib—Palpitations—Memantine—Alzheimer's disease	0.000106	0.000502	CcSEcCtD
Bortezomib—Malaise—Rivastigmine—Alzheimer's disease	0.000106	0.000501	CcSEcCtD
Bortezomib—Nervous system disorder—Donepezil—Alzheimer's disease	0.000106	0.0005	CcSEcCtD
Bortezomib—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000105	0.0005	CcSEcCtD
Bortezomib—Vertigo—Rivastigmine—Alzheimer's disease	0.000105	0.000499	CcSEcCtD
Bortezomib—Loss of consciousness—Memantine—Alzheimer's disease	0.000105	0.000499	CcSEcCtD
Bortezomib—Syncope—Rivastigmine—Alzheimer's disease	0.000105	0.000498	CcSEcCtD
Bortezomib—Cough—Memantine—Alzheimer's disease	0.000104	0.000495	CcSEcCtD
Bortezomib—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000104	0.000493	CcSEcCtD
Bortezomib—Convulsion—Memantine—Alzheimer's disease	0.000104	0.000492	CcSEcCtD
Bortezomib—Palpitations—Rivastigmine—Alzheimer's disease	0.000104	0.000491	CcSEcCtD
Bortezomib—Hypertension—Memantine—Alzheimer's disease	0.000103	0.00049	CcSEcCtD
Bortezomib—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000103	0.000488	CcSEcCtD
Bortezomib—Anorexia—Donepezil—Alzheimer's disease	0.000103	0.000486	CcSEcCtD
Bortezomib—Hypersensitivity—Galantamine—Alzheimer's disease	0.000102	0.000485	CcSEcCtD
Bortezomib—Cough—Rivastigmine—Alzheimer's disease	0.000102	0.000485	CcSEcCtD
Bortezomib—Myalgia—Memantine—Alzheimer's disease	0.000102	0.000483	CcSEcCtD
Bortezomib—Arthralgia—Memantine—Alzheimer's disease	0.000102	0.000483	CcSEcCtD
Bortezomib—Chest pain—Memantine—Alzheimer's disease	0.000102	0.000483	CcSEcCtD
Bortezomib—Anxiety—Memantine—Alzheimer's disease	0.000102	0.000482	CcSEcCtD
Bortezomib—Convulsion—Rivastigmine—Alzheimer's disease	0.000101	0.000481	CcSEcCtD
Bortezomib—Hypertension—Rivastigmine—Alzheimer's disease	0.000101	0.000479	CcSEcCtD
Bortezomib—Discomfort—Memantine—Alzheimer's disease	0.000101	0.000477	CcSEcCtD
Bortezomib—Hypotension—Donepezil—Alzheimer's disease	0.000101	0.000477	CcSEcCtD
Bortezomib—Chest pain—Rivastigmine—Alzheimer's disease	9.97e-05	0.000473	CcSEcCtD
Bortezomib—Myalgia—Rivastigmine—Alzheimer's disease	9.97e-05	0.000473	CcSEcCtD
Bortezomib—Arthralgia—Rivastigmine—Alzheimer's disease	9.97e-05	0.000473	CcSEcCtD
Bortezomib—Asthenia—Galantamine—Alzheimer's disease	9.96e-05	0.000472	CcSEcCtD
Bortezomib—Anxiety—Rivastigmine—Alzheimer's disease	9.94e-05	0.000471	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	9.9e-05	0.00047	CcSEcCtD
Bortezomib—Confusional state—Memantine—Alzheimer's disease	9.85e-05	0.000467	CcSEcCtD
Bortezomib—Discomfort—Rivastigmine—Alzheimer's disease	9.85e-05	0.000467	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	9.81e-05	0.000465	CcSEcCtD
Bortezomib—Oedema—Memantine—Alzheimer's disease	9.77e-05	0.000463	CcSEcCtD
Bortezomib—Insomnia—Donepezil—Alzheimer's disease	9.73e-05	0.000461	CcSEcCtD
Bortezomib—Infection—Memantine—Alzheimer's disease	9.71e-05	0.00046	CcSEcCtD
Bortezomib—Paraesthesia—Donepezil—Alzheimer's disease	9.66e-05	0.000458	CcSEcCtD
Bortezomib—Confusional state—Rivastigmine—Alzheimer's disease	9.64e-05	0.000457	CcSEcCtD
Bortezomib—Shock—Memantine—Alzheimer's disease	9.61e-05	0.000456	CcSEcCtD
Bortezomib—Dyspnoea—Donepezil—Alzheimer's disease	9.59e-05	0.000455	CcSEcCtD
Bortezomib—Nervous system disorder—Memantine—Alzheimer's disease	9.58e-05	0.000454	CcSEcCtD
Bortezomib—Thrombocytopenia—Memantine—Alzheimer's disease	9.57e-05	0.000454	CcSEcCtD
Bortezomib—Oedema—Rivastigmine—Alzheimer's disease	9.56e-05	0.000453	CcSEcCtD
Bortezomib—Tachycardia—Memantine—Alzheimer's disease	9.54e-05	0.000452	CcSEcCtD
Bortezomib—Diarrhoea—Galantamine—Alzheimer's disease	9.5e-05	0.00045	CcSEcCtD
Bortezomib—Infection—Rivastigmine—Alzheimer's disease	9.5e-05	0.00045	CcSEcCtD
Bortezomib—Skin disorder—Memantine—Alzheimer's disease	9.49e-05	0.00045	CcSEcCtD
Bortezomib—Dyspepsia—Donepezil—Alzheimer's disease	9.47e-05	0.000449	CcSEcCtD
Bortezomib—Hyperhidrosis—Memantine—Alzheimer's disease	9.45e-05	0.000448	CcSEcCtD
Bortezomib—Shock—Rivastigmine—Alzheimer's disease	9.4e-05	0.000446	CcSEcCtD
Bortezomib—Nervous system disorder—Rivastigmine—Alzheimer's disease	9.37e-05	0.000444	CcSEcCtD
Bortezomib—Thrombocytopenia—Rivastigmine—Alzheimer's disease	9.36e-05	0.000444	CcSEcCtD
Bortezomib—Decreased appetite—Donepezil—Alzheimer's disease	9.36e-05	0.000444	CcSEcCtD
Bortezomib—Tachycardia—Rivastigmine—Alzheimer's disease	9.33e-05	0.000442	CcSEcCtD
Bortezomib—Anorexia—Memantine—Alzheimer's disease	9.31e-05	0.000442	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Donepezil—Alzheimer's disease	9.29e-05	0.00044	CcSEcCtD
Bortezomib—Skin disorder—Rivastigmine—Alzheimer's disease	9.29e-05	0.00044	CcSEcCtD
Bortezomib—Fatigue—Donepezil—Alzheimer's disease	9.28e-05	0.00044	CcSEcCtD
Bortezomib—Hyperhidrosis—Rivastigmine—Alzheimer's disease	9.24e-05	0.000438	CcSEcCtD
Bortezomib—Pain—Donepezil—Alzheimer's disease	9.2e-05	0.000436	CcSEcCtD
Bortezomib—Constipation—Donepezil—Alzheimer's disease	9.2e-05	0.000436	CcSEcCtD
Bortezomib—Dizziness—Galantamine—Alzheimer's disease	9.18e-05	0.000435	CcSEcCtD
Bortezomib—Hypotension—Memantine—Alzheimer's disease	9.13e-05	0.000433	CcSEcCtD
Bortezomib—Anorexia—Rivastigmine—Alzheimer's disease	9.11e-05	0.000432	CcSEcCtD
Bortezomib—Hypotension—Rivastigmine—Alzheimer's disease	8.93e-05	0.000423	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Memantine—Alzheimer's disease	8.9e-05	0.000422	CcSEcCtD
Bortezomib—Feeling abnormal—Donepezil—Alzheimer's disease	8.87e-05	0.00042	CcSEcCtD
Bortezomib—Insomnia—Memantine—Alzheimer's disease	8.84e-05	0.000419	CcSEcCtD
Bortezomib—Vomiting—Galantamine—Alzheimer's disease	8.83e-05	0.000419	CcSEcCtD
Bortezomib—Gastrointestinal pain—Donepezil—Alzheimer's disease	8.8e-05	0.000417	CcSEcCtD
Bortezomib—Paraesthesia—Memantine—Alzheimer's disease	8.77e-05	0.000416	CcSEcCtD
Bortezomib—Rash—Galantamine—Alzheimer's disease	8.76e-05	0.000415	CcSEcCtD
Bortezomib—Dermatitis—Galantamine—Alzheimer's disease	8.75e-05	0.000415	CcSEcCtD
Bortezomib—Dyspnoea—Memantine—Alzheimer's disease	8.71e-05	0.000413	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	8.71e-05	0.000413	CcSEcCtD
Bortezomib—Headache—Galantamine—Alzheimer's disease	8.7e-05	0.000412	CcSEcCtD
Bortezomib—Insomnia—Rivastigmine—Alzheimer's disease	8.65e-05	0.00041	CcSEcCtD
Bortezomib—Dyspepsia—Memantine—Alzheimer's disease	8.6e-05	0.000408	CcSEcCtD
Bortezomib—Paraesthesia—Rivastigmine—Alzheimer's disease	8.58e-05	0.000407	CcSEcCtD
Bortezomib—Urticaria—Donepezil—Alzheimer's disease	8.55e-05	0.000405	CcSEcCtD
Bortezomib—Dyspnoea—Rivastigmine—Alzheimer's disease	8.52e-05	0.000404	CcSEcCtD
Bortezomib—Body temperature increased—Donepezil—Alzheimer's disease	8.51e-05	0.000403	CcSEcCtD
Bortezomib—Abdominal pain—Donepezil—Alzheimer's disease	8.51e-05	0.000403	CcSEcCtD
Bortezomib—Decreased appetite—Memantine—Alzheimer's disease	8.49e-05	0.000403	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Memantine—Alzheimer's disease	8.44e-05	0.0004	CcSEcCtD
Bortezomib—Fatigue—Memantine—Alzheimer's disease	8.42e-05	0.000399	CcSEcCtD
Bortezomib—Dyspepsia—Rivastigmine—Alzheimer's disease	8.41e-05	0.000399	CcSEcCtD
Bortezomib—Pain—Memantine—Alzheimer's disease	8.36e-05	0.000396	CcSEcCtD
Bortezomib—Constipation—Memantine—Alzheimer's disease	8.36e-05	0.000396	CcSEcCtD
Bortezomib—Decreased appetite—Rivastigmine—Alzheimer's disease	8.31e-05	0.000394	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	8.25e-05	0.000391	CcSEcCtD
Bortezomib—Nausea—Galantamine—Alzheimer's disease	8.25e-05	0.000391	CcSEcCtD
Bortezomib—Fatigue—Rivastigmine—Alzheimer's disease	8.24e-05	0.000391	CcSEcCtD
Bortezomib—Pain—Rivastigmine—Alzheimer's disease	8.17e-05	0.000388	CcSEcCtD
Bortezomib—Constipation—Rivastigmine—Alzheimer's disease	8.17e-05	0.000388	CcSEcCtD
Bortezomib—Feeling abnormal—Memantine—Alzheimer's disease	8.05e-05	0.000382	CcSEcCtD
Bortezomib—Gastrointestinal pain—Memantine—Alzheimer's disease	7.99e-05	0.000379	CcSEcCtD
Bortezomib—Hypersensitivity—Donepezil—Alzheimer's disease	7.93e-05	0.000376	CcSEcCtD
Bortezomib—Feeling abnormal—Rivastigmine—Alzheimer's disease	7.88e-05	0.000373	CcSEcCtD
Bortezomib—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	7.82e-05	0.000371	CcSEcCtD
Bortezomib—Urticaria—Memantine—Alzheimer's disease	7.76e-05	0.000368	CcSEcCtD
Bortezomib—Abdominal pain—Memantine—Alzheimer's disease	7.72e-05	0.000366	CcSEcCtD
Bortezomib—Body temperature increased—Memantine—Alzheimer's disease	7.72e-05	0.000366	CcSEcCtD
Bortezomib—Asthenia—Donepezil—Alzheimer's disease	7.72e-05	0.000366	CcSEcCtD
Bortezomib—Pruritus—Donepezil—Alzheimer's disease	7.61e-05	0.000361	CcSEcCtD
Bortezomib—Urticaria—Rivastigmine—Alzheimer's disease	7.59e-05	0.00036	CcSEcCtD
Bortezomib—Abdominal pain—Rivastigmine—Alzheimer's disease	7.56e-05	0.000358	CcSEcCtD
Bortezomib—Body temperature increased—Rivastigmine—Alzheimer's disease	7.56e-05	0.000358	CcSEcCtD
Bortezomib—Diarrhoea—Donepezil—Alzheimer's disease	7.36e-05	0.000349	CcSEcCtD
Bortezomib—Hypersensitivity—Memantine—Alzheimer's disease	7.2e-05	0.000341	CcSEcCtD
Bortezomib—Dizziness—Donepezil—Alzheimer's disease	7.12e-05	0.000337	CcSEcCtD
Bortezomib—Hypersensitivity—Rivastigmine—Alzheimer's disease	7.04e-05	0.000334	CcSEcCtD
Bortezomib—Asthenia—Memantine—Alzheimer's disease	7.01e-05	0.000332	CcSEcCtD
Bortezomib—Pruritus—Memantine—Alzheimer's disease	6.91e-05	0.000328	CcSEcCtD
Bortezomib—Asthenia—Rivastigmine—Alzheimer's disease	6.86e-05	0.000325	CcSEcCtD
Bortezomib—Vomiting—Donepezil—Alzheimer's disease	6.84e-05	0.000324	CcSEcCtD
Bortezomib—Rash—Donepezil—Alzheimer's disease	6.79e-05	0.000322	CcSEcCtD
Bortezomib—Dermatitis—Donepezil—Alzheimer's disease	6.78e-05	0.000321	CcSEcCtD
Bortezomib—Pruritus—Rivastigmine—Alzheimer's disease	6.76e-05	0.000321	CcSEcCtD
Bortezomib—Headache—Donepezil—Alzheimer's disease	6.74e-05	0.00032	CcSEcCtD
Bortezomib—Diarrhoea—Memantine—Alzheimer's disease	6.69e-05	0.000317	CcSEcCtD
Bortezomib—Diarrhoea—Rivastigmine—Alzheimer's disease	6.54e-05	0.00031	CcSEcCtD
Bortezomib—Dizziness—Memantine—Alzheimer's disease	6.46e-05	0.000306	CcSEcCtD
Bortezomib—Nausea—Donepezil—Alzheimer's disease	6.39e-05	0.000303	CcSEcCtD
Bortezomib—Dizziness—Rivastigmine—Alzheimer's disease	6.32e-05	0.0003	CcSEcCtD
Bortezomib—Vomiting—Memantine—Alzheimer's disease	6.21e-05	0.000295	CcSEcCtD
Bortezomib—Rash—Memantine—Alzheimer's disease	6.16e-05	0.000292	CcSEcCtD
Bortezomib—Dermatitis—Memantine—Alzheimer's disease	6.16e-05	0.000292	CcSEcCtD
Bortezomib—Headache—Memantine—Alzheimer's disease	6.12e-05	0.00029	CcSEcCtD
Bortezomib—Vomiting—Rivastigmine—Alzheimer's disease	6.08e-05	0.000288	CcSEcCtD
Bortezomib—Rash—Rivastigmine—Alzheimer's disease	6.03e-05	0.000286	CcSEcCtD
Bortezomib—Dermatitis—Rivastigmine—Alzheimer's disease	6.02e-05	0.000285	CcSEcCtD
Bortezomib—Headache—Rivastigmine—Alzheimer's disease	5.99e-05	0.000284	CcSEcCtD
Bortezomib—Nausea—Memantine—Alzheimer's disease	5.8e-05	0.000275	CcSEcCtD
Bortezomib—Nausea—Rivastigmine—Alzheimer's disease	5.68e-05	0.000269	CcSEcCtD
Bortezomib—CYP1A1—Metabolism—BCHE—Alzheimer's disease	5.27e-06	4.44e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	5.26e-06	4.44e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—A2M—Alzheimer's disease	5.23e-06	4.41e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS1—Alzheimer's disease	5.19e-06	4.38e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO1—Alzheimer's disease	5.19e-06	4.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—A2M—Alzheimer's disease	5.19e-06	4.38e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—Alzheimer's disease	5.12e-06	4.32e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—Alzheimer's disease	5.1e-06	4.3e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP2D6—Alzheimer's disease	5.09e-06	4.3e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—Alzheimer's disease	5.09e-06	4.29e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—Alzheimer's disease	5.09e-06	4.29e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—Alzheimer's disease	5.09e-06	4.29e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—Alzheimer's disease	5.07e-06	4.28e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	5.07e-06	4.28e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—Alzheimer's disease	5.06e-06	4.27e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—Alzheimer's disease	5.06e-06	4.27e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—Alzheimer's disease	5.04e-06	4.25e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—Alzheimer's disease	5.03e-06	4.25e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—Alzheimer's disease	5.03e-06	4.24e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—Alzheimer's disease	5.02e-06	4.23e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—Alzheimer's disease	5.01e-06	4.23e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—Alzheimer's disease	5.01e-06	4.23e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—Alzheimer's disease	5e-06	4.22e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—Alzheimer's disease	4.98e-06	4.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TPI1—Alzheimer's disease	4.97e-06	4.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CHAT—Alzheimer's disease	4.97e-06	4.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PLCB1—Alzheimer's disease	4.97e-06	4.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ACHE—Alzheimer's disease	4.95e-06	4.17e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—INPP5D—Alzheimer's disease	4.89e-06	4.13e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.88e-06	4.11e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MTHFR—Alzheimer's disease	4.83e-06	4.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—BCHE—Alzheimer's disease	4.83e-06	4.07e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCA1—Alzheimer's disease	4.82e-06	4.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MAOB—Alzheimer's disease	4.77e-06	4.02e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—Alzheimer's disease	4.7e-06	3.97e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—Alzheimer's disease	4.68e-06	3.95e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—Alzheimer's disease	4.67e-06	3.94e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—Alzheimer's disease	4.66e-06	3.93e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—Alzheimer's disease	4.65e-06	3.92e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO1—Alzheimer's disease	4.64e-06	3.91e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS1—Alzheimer's disease	4.64e-06	3.91e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	4.62e-06	3.9e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—Alzheimer's disease	4.62e-06	3.9e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GAPDH—Alzheimer's disease	4.59e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP3—Alzheimer's disease	4.58e-06	3.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP3—Alzheimer's disease	4.58e-06	3.86e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP3—Alzheimer's disease	4.58e-06	3.86e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PLCB1—Alzheimer's disease	4.56e-06	3.84e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ACHE—Alzheimer's disease	4.55e-06	3.84e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP2D6—Alzheimer's disease	4.55e-06	3.84e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	4.54e-06	3.83e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CALM1—Alzheimer's disease	4.51e-06	3.81e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ACHE—Alzheimer's disease	4.51e-06	3.81e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP3—Alzheimer's disease	4.51e-06	3.81e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	4.5e-06	3.8e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—Alzheimer's disease	4.5e-06	3.79e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	4.49e-06	3.79e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.47e-06	3.77e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—INPP5D—Alzheimer's disease	4.46e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CAV1—Alzheimer's disease	4.46e-06	3.76e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—A2M—Alzheimer's disease	4.43e-06	3.74e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCA1—Alzheimer's disease	4.42e-06	3.73e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—BCHE—Alzheimer's disease	4.31e-06	3.64e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO1—Alzheimer's disease	4.26e-06	3.6e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	4.26e-06	3.6e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO1—Alzheimer's disease	4.23e-06	3.57e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS1—Alzheimer's disease	4.23e-06	3.57e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MAPK8—Alzheimer's disease	4.2e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MAPK8—Alzheimer's disease	4.2e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MAPK8—Alzheimer's disease	4.2e-06	3.55e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—Alzheimer's disease	4.15e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—Alzheimer's disease	4.15e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—Alzheimer's disease	4.15e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARGC1A—Alzheimer's disease	4.15e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2D6—Alzheimer's disease	4.15e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MAPK8—Alzheimer's disease	4.15e-06	3.5e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HMOX1—Alzheimer's disease	4.13e-06	3.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—Alzheimer's disease	4.09e-06	3.46e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PLCB1—Alzheimer's disease	4.07e-06	3.43e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	3.99e-06	3.37e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—BCHE—Alzheimer's disease	3.96e-06	3.35e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	3.95e-06	3.33e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCA1—Alzheimer's disease	3.94e-06	3.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—BCHE—Alzheimer's disease	3.93e-06	3.32e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—Alzheimer's disease	3.92e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—Alzheimer's disease	3.91e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—Alzheimer's disease	3.89e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—Alzheimer's disease	3.88e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—Alzheimer's disease	3.88e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—Alzheimer's disease	3.88e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—Alzheimer's disease	3.87e-06	3.27e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—Alzheimer's disease	3.87e-06	3.27e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ACHE—Alzheimer's disease	3.86e-06	3.25e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—Alzheimer's disease	3.85e-06	3.25e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—INS—Alzheimer's disease	3.84e-06	3.24e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TPI1—Alzheimer's disease	3.84e-06	3.24e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CHAT—Alzheimer's disease	3.84e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—Alzheimer's disease	3.83e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—Alzheimer's disease	3.83e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—Alzheimer's disease	3.83e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—Alzheimer's disease	3.83e-06	3.24e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—Alzheimer's disease	3.83e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—Alzheimer's disease	3.83e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—Alzheimer's disease	3.83e-06	3.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—Alzheimer's disease	3.83e-06	3.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—INPP5D—Alzheimer's disease	3.81e-06	3.22e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—Alzheimer's disease	3.81e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—Alzheimer's disease	3.81e-06	3.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—Alzheimer's disease	3.81e-06	3.21e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARGC1A—Alzheimer's disease	3.81e-06	3.21e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—Alzheimer's disease	3.79e-06	3.2e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—Alzheimer's disease	3.78e-06	3.19e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—LPL—Alzheimer's disease	3.78e-06	3.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—Alzheimer's disease	3.78e-06	3.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—Alzheimer's disease	3.76e-06	3.17e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	3.74e-06	3.16e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PLCB1—Alzheimer's disease	3.71e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MAOB—Alzheimer's disease	3.68e-06	3.1e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	3.64e-06	3.07e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	3.63e-06	3.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO1—Alzheimer's disease	3.61e-06	3.05e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	3.61e-06	3.05e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCA1—Alzheimer's disease	3.59e-06	3.03e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—Alzheimer's disease	3.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—Alzheimer's disease	3.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—Alzheimer's disease	3.56e-06	3.01e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—Alzheimer's disease	3.54e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	3.54e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	3.54e-06	2.99e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—Alzheimer's disease	3.54e-06	2.98e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—Alzheimer's disease	3.54e-06	2.98e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—Alzheimer's disease	3.54e-06	2.98e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—Alzheimer's disease	3.53e-06	2.98e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—Alzheimer's disease	3.51e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—Alzheimer's disease	3.51e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—Alzheimer's disease	3.49e-06	2.94e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—LPL—Alzheimer's disease	3.47e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—A2M—Alzheimer's disease	3.42e-06	2.89e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—Alzheimer's disease	3.4e-06	2.87e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARGC1A—Alzheimer's disease	3.4e-06	2.87e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—Alzheimer's disease	3.38e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—Alzheimer's disease	3.37e-06	2.84e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—BCHE—Alzheimer's disease	3.36e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—Alzheimer's disease	3.27e-06	2.76e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—Alzheimer's disease	3.25e-06	2.74e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—Alzheimer's disease	3.24e-06	2.73e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CALM1—Alzheimer's disease	3.18e-06	2.68e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	3.17e-06	2.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—Alzheimer's disease	3.17e-06	2.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAV1—Alzheimer's disease	3.14e-06	2.65e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	3.12e-06	2.64e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—Alzheimer's disease	3.12e-06	2.63e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	3.11e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	3.11e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARGC1A—Alzheimer's disease	3.1e-06	2.61e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—LPL—Alzheimer's disease	3.09e-06	2.61e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—Alzheimer's disease	3.08e-06	2.6e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—Alzheimer's disease	3.08e-06	2.6e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	3.07e-06	2.59e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ACHE—Alzheimer's disease	2.98e-06	2.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—Alzheimer's disease	2.96e-06	2.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—Alzheimer's disease	2.96e-06	2.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—Alzheimer's disease	2.96e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	2.94e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—Alzheimer's disease	2.93e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—Alzheimer's disease	2.93e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—Alzheimer's disease	2.93e-06	2.48e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—Alzheimer's disease	2.92e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CALM1—Alzheimer's disease	2.92e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—Alzheimer's disease	2.9e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—Alzheimer's disease	2.89e-06	2.44e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAV1—Alzheimer's disease	2.88e-06	2.43e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—LPL—Alzheimer's disease	2.85e-06	2.4e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—LPL—Alzheimer's disease	2.82e-06	2.38e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—Alzheimer's disease	2.79e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	2.79e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—Alzheimer's disease	2.79e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—Alzheimer's disease	2.76e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	2.73e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—INS—Alzheimer's disease	2.71e-06	2.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—Alzheimer's disease	2.69e-06	2.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—Alzheimer's disease	2.69e-06	2.27e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—Alzheimer's disease	2.69e-06	2.27e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	2.65e-06	2.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—Alzheimer's disease	2.65e-06	2.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	2.64e-06	2.22e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CALM1—Alzheimer's disease	2.6e-06	2.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—Alzheimer's disease	2.59e-06	2.19e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—BCHE—Alzheimer's disease	2.59e-06	2.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAV1—Alzheimer's disease	2.57e-06	2.17e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	2.56e-06	2.16e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—Alzheimer's disease	2.54e-06	2.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—Alzheimer's disease	2.53e-06	2.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—INS—Alzheimer's disease	2.48e-06	2.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—Alzheimer's disease	2.48e-06	2.09e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—Alzheimer's disease	2.48e-06	2.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—Alzheimer's disease	2.48e-06	2.09e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	2.45e-06	2.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—Alzheimer's disease	2.44e-06	2.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—LPL—Alzheimer's disease	2.41e-06	2.03e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CALM1—Alzheimer's disease	2.39e-06	2.02e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—Alzheimer's disease	2.38e-06	2.01e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—Alzheimer's disease	2.37e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CALM1—Alzheimer's disease	2.37e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	2.37e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—Alzheimer's disease	2.36e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAV1—Alzheimer's disease	2.36e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAV1—Alzheimer's disease	2.34e-06	1.98e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—Alzheimer's disease	2.26e-06	1.91e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—INS—Alzheimer's disease	2.22e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—Alzheimer's disease	2.18e-06	1.84e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—Alzheimer's disease	2.17e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	2.17e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—Alzheimer's disease	2.08e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—Alzheimer's disease	2.06e-06	1.74e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	2.04e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—INS—Alzheimer's disease	2.04e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	2.03e-06	1.72e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CALM1—Alzheimer's disease	2.03e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—Alzheimer's disease	2.02e-06	1.7e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—INS—Alzheimer's disease	2.02e-06	1.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAV1—Alzheimer's disease	2e-06	1.69e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—Alzheimer's disease	1.99e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—Alzheimer's disease	1.94e-06	1.64e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—LPL—Alzheimer's disease	1.86e-06	1.57e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—Alzheimer's disease	1.79e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—Alzheimer's disease	1.78e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—Alzheimer's disease	1.77e-06	1.49e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—Alzheimer's disease	1.76e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—INS—Alzheimer's disease	1.73e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	1.67e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	1.63e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—Alzheimer's disease	1.62e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CALM1—Alzheimer's disease	1.56e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—Alzheimer's disease	1.56e-06	1.32e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—Alzheimer's disease	1.55e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAV1—Alzheimer's disease	1.54e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—Alzheimer's disease	1.51e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	1.38e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—Alzheimer's disease	1.36e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—INS—Alzheimer's disease	1.33e-06	1.12e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—Alzheimer's disease	1.17e-06	9.86e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—Alzheimer's disease	1.09e-06	9.21e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	1.07e-06	9.02e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—Alzheimer's disease	1e-06	8.44e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—Alzheimer's disease	8.93e-07	7.53e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—Alzheimer's disease	8.21e-07	6.93e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—Alzheimer's disease	8.14e-07	6.87e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—Alzheimer's disease	6.96e-07	5.87e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—Alzheimer's disease	5.37e-07	4.53e-06	CbGpPWpGaD
